AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01834261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon Nasal Spray, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study NCT01834261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon Nasal Spray, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study NCT01834261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon Placebo Formulation, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study NCT01834261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon Placebo Formulation, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study NCT02536794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7H1 Monoclonal Antibody MEDI4736
Description: Given IV
Study NCT02536794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02536794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02536794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT04360720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Monotherapy
Description: All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12.
Study NCT04106037 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT00026338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: 150 mg po daily
Study NCT00026338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
Study NCT03609840 — intervention group
Intervention type: DRUG
Intervention: Thiotepa
Description: Given IV
Study NCT00607594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
Study NCT03155477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and C. Xanthorrhiza
Description: Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
Study NCT03155477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol and placebo
Description: Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
Study NCT04003571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality with Functional Electrical Stimulation group
Description: Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
Study NCT04003571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
Study NCT02646059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
Study NCT02646059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone
Description: Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
Study NCT03268187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: The skin conductance of the patient is measured and fed back to the patient via screen.
Study NCT03268187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The skin conductance of the patient is measured and fed back to the patient via screen.
Study NCT03268187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Alert Training
Description: Self-Alert Training
Study NCT03268187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Relaxation Training
Study NCT02984137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
Study NCT02984137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
Study NCT02984137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
Study NCT02007772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nHF
Description: nasal high-flow is used over a period of 6 weeks (outpatient)
Study NCT02007772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHF
Description: nasal high-flow is used over a period of 6 weeks (outpatient)
Study NCT02007772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: BiPAP is used over a period of 6 weeks (outpatient)
Study NCT02007772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP is used over a period of 6 weeks (outpatient)
Study NCT03454958 — intervention group
Intervention type: OTHER
Intervention: Measurements of body composition
Description: Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
Study NCT01026597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Study NCT01026597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Study NCT03808857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
Study NCT02339207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-335 matching placebo
Study NCT02339207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Study NCT04324320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: medical assessment
Description: medical assessment includes the collection of~* sociodemographic data~* anthropometric data (weight, height, body mass index)~* medical data~* psycho-oncologic basis assessment (PO-BADO questionnaire)~* pain assessment (VAS: visual analogue scale)~* 3 functional tests:~  * handgrip strength~ * 6 Minute Walking Test~ * Timed Get up and Go Test
Study NCT04324320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: psychological assessment
Description: psychological assessment includes several standardized screening and assessment questionnaires and tools:~* quality of life: SF-36~* anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~* subjective stress perception: Perceived Stress Scale (PSS-10)~* resilience: resilience scale (RS-13)~* fatigue: Brief Fatigue Inventory (BFI)~* disability related to pain: Pain Disability Index (PDI)~* workability: Work Ability Index - short version (WAI-K)~* psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))
Study NCT00215956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
Study NCT00215956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation
Description: Preoperative radiation
Study NCT00215956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
Study NCT00771602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
Study NCT00771602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
Study NCT02104102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
Study NCT02104102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Hands movements.
Study NCT03748667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: White light endoscopy (WLE)
Description: Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
Study NCT03748667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)
Description: Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
Study NCT04399005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: after-each-case room disinfection
Description: After-each-case room disinfection was defined as after completing each case.
Study NCT04399005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily room disinfection
Description: Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
Study NCT04549441 — intervention group
Intervention type: PROCEDURE
Intervention: Distal radius fracture plating surgery
Description: We performed open reduction and plating surgery for the distal radius fracture.
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: 1 week extended wear contact lens
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A
Description: 1 week extended wear contact lens
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: 1 week extended wear contact lens
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: 1 week extended wear contact lens
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: 1 week extended wear contact lens
Study NCT00762788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: 1 week extended wear contact lens
Study NCT04039269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative video information
Study NCT01625182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg capsules
Study NCT01625182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching placebo capsules
Study NCT01235819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Exenatide Sitagliptin
Study NCT01235819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg per day oral
Study NCT01235819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 10 micrograms daily twice
Study NCT01285089 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
Study NCT04163380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A rabbit polyclonal antibody to lymphocytes
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
Study NCT00787722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: A corticosteroid medication used to suppress the immune system and decrease inflammation
Study NCT04199715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heplisav-B
Description: This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
Study NCT04061629 — intervention group
Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.
Study NCT06109688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
Study NCT06109688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
Study NCT02574208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing by ELISA
Description: HIV testing randomized between ELISA or rapid test
Study NCT02574208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIV testing by rapid test
Description: HIV testing randomized between ELISA or rapid test
Study NCT02967887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and 5-fluorouracil
Description: Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
Study NCT04407520 — intervention group
Intervention type: OTHER
Intervention: No patient treatment is associated with the study
Description: No patient treatment is associated with the study.
Study NCT03669679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reduction
Description: breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
Study NCT00546273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
Study NCT00546273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
Study NCT00546273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
Study NCT00546273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
Study NCT00546273 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo of the vaccine RUTI
Description: placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
Study NCT00820092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 1.0
Description: 24 hour infusion
Study NCT00820092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 2.0
Description: 24 hour infusion
Study NCT00820092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 3.0
Description: 24 hour infusion
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: cutaneous parameters of psoriasis (exposure)
Description: characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: comorbidity (exposure)
Description: medical and medication history, current and previous comorbidity
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: family history (exposure)
Description: Family history of PsC, PsA, IBD, AS, and uveitis
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: lifestyle (exposure)
Description: * Intoxications~* Lifestyle: occupation and injuries, sport and physical hobbies
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: patient reported outcomes (exposure)
Description: VAS-score on fatigue, PsC severity, joint pain and general well-being
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: inflammatory markers (exposure)
Description: Measurements of inflammatory and bone remodeling markers in serum and plasma
Study NCT03816917 — intervention group
Intervention type: OTHER
Intervention: genetic (exposure)
Description: Assessment of known HLA- and SNP-associations with PsA or PsA
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Arm B 1250mg/d PO Arm C 750mg/d PO
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: Arm B 1250mg/d PO Arm C 750mg/d PO
Study NCT00429299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/sqm 1 hour infusion for 12 weeks
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80mg/sqm 1 hour infusion for 12 weeks